| Purity | ≥98% |
| Molecular Weight | 4,813.48 Da |
| Category | GLP-1/GIP Dual Agonists |
Tirzepatide
A dual GIP and GLP-1 receptor agonist research peptide for studying combined incretin receptor pharmacology and metabolic signaling.
Starting from $54.99
For research use only. Not for human consumption.
Storage Conditions
Store lyophilized at −20 °C. After reconstitution, store at 4 °C and use within 28 days. Do not freeze reconstituted solution. Protect from light.
Research Overview
Tirzepatide is a synthetic 39-amino acid peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The molecule incorporates a C20 fatty diacid moiety that promotes albumin binding, providing an extended plasma half-life suitable for once-weekly dosing in clinical studies.
As a dual incretin receptor agonist, tirzepatide is a valuable research tool for studying the synergistic or additive effects of GIP and GLP-1 receptor co-activation on metabolic endpoints. Research has explored differential receptor activation ratios, receptor internalization dynamics, and downstream cAMP signaling relative to selective GIP or GLP-1 agonists.
Preclinical studies in rodent and non-human primate models have examined tirzepatide's effects on body weight, glycemic control, lipid metabolism, and hepatic steatosis. The dual mechanism provides a pharmacological tool to dissect the individual and combined contributions of GIP and GLP-1 receptor pathways in metabolic homeostasis.
Supplied as lyophilized powder for research use only.
Research use only. This product is intended for in vitro and laboratory research purposes only. It is not approved by the FDA for human or veterinary use. It is not a drug, food, or cosmetic, and may not be misbranded, misused, or sold for purposes other than research.
All information provided is for research and educational purposes only and does not constitute medical advice.